Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Sickle cell pain in the emergency department
source: National Institute for Children’s Health Quality
year: 2015
summary/abstract:Sickle cell disease is characterized by unpredictable episodes of extreme pain, known as acute vaso-occlusive episodes (VOE) or pain episodes, caused when sickled red blood cells are unable to move freely through blood vessels. In addition to pain, these changes at the cellular level can also lead to organ damage, stroke and even death. Pain episodes are the most common reason for emergency department (ED) visits and hospitalizations for patients with sickle cell disease. Detailed guidelines and quality indicators for the management of pain episodes currently exist, but both pediatric and adult patients with the disease often experience prolonged periods of waiting for treatment in the emergency department and ineffective treatment of their pain.
Delays in treatment are often due to systemic factors, such as the lack of a clear treatment protocol or limited provider experience in treating sickle cell diseaserelated pain. Prolonged waits for effective pain relief can lead to unnecessary suffering, hospitalizations, chronic pain syndromes, other complications and increased health care costs.1,8,10-12 Ensuring patients receive timely, effective pain relief is one of the most important elements of delivering high quality care to individuals with sickle cell disease in the emergency department.
read more
Related Content
-
Sickle cell disease in the emergency departmentAcute painful episodes are the most comm...
-
Quality of care in sickle cell disease: Cross-sectional study and development of a measure for adults reporting on a...Documented deficiencies in adult sickle ...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
SCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses ShowStarting treatment with rivipansel (GMI-...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
My medical school lesson was tinged with racism. Did that affect how I treated a sickle cell patient years later?The young woman was curled up in a ball....
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.